Factors associated with frailty in rheumatoid arthritis patients with decreased renal function

Mod Rheumatol. 2023 Mar 2;33(2):323-329. doi: 10.1093/mr/roac018.

Abstract

Objectives: To investigate factors associated with frailty in rheumatoid arthritis (RA) patients with decreased renal function.

Methods: RA patients who visited outpatient clinics from June to August 2021 were included (N = 625). Patients with estimated glomerular filtration rate <60 ml/min/1.73 m2 were defined as having decreased renal function (N = 221) and divided into the non-frailty (N = 153) and frailty (N = 58) groups. Patient characteristics were compared between the two groups by univariate analysis. Significant factors in univariate analysis were assessed by logistic regression analysis to determine their association with frailty in patients with decreased renal function.

Results: Patients in the frailty group were older (74.0 vs.79.0 years) and had a longer duration of disease (11.1 vs. 17.8 years), higher Disease Activity Score erythrocyte sedimentation rate (DAS28-ESR; 2.99 vs. 3.80), higher Health Assessment Questionnaire Disability Index (0.42 vs. 1.43), and a lower rate of methotrexate (MTX) use (46.4% vs. 25.9) compared to those in the non-frailty group. Factors associated with frailty in patients with decreased renal function were age (odds ratio: 1.07), duration of disease (1.06), DAS28-ESR (1.85), and MTX use (0.42).

Conclusions: Among factors associated with frailty in RA patients with decreased renal function, improving DAS28-ESR is likely to be the most feasible approach to promote recovery from frailty (200/200 words).

Keywords: Chronic kidney disease; frailty; methotrexate; rheumatoid arthritis.

MeSH terms

  • Antirheumatic Agents* / therapeutic use
  • Arthritis, Rheumatoid* / complications
  • Arthritis, Rheumatoid* / drug therapy
  • Humans
  • Kidney / physiology
  • Methotrexate / therapeutic use
  • Research Design
  • Treatment Outcome

Substances

  • Antirheumatic Agents
  • Methotrexate